Form 4: Baker Bros. Advisors Acquires Warrants in Madrigal Pharmaceuticals

Baker Bros. Advisors LP reports the acquisition of warrants to purchase common stock in Madrigal Pharmaceuticals through an underwritten offering.

Summary

• Baker Bros. Advisors LP filed a Form 4 with the SEC on March 25, 2024, reporting transactions in Madrigal Pharmaceuticals, Inc. (MDGL) common stock.
• The transactions involved the acquisition of warrants to purchase common stock at an exercise price of $0.0001 per share.
• 86,741 warrants were acquired by 667, L.P. and 970,951 warrants were acquired by Baker Brothers Life Sciences, L.P. at a price of $259.9999 per warrant on March 21, 2024.
• The warrants are exercisable at any time on a 1-for-1 basis into common stock, subject to a 9.99% ownership limitation (which can be increased to 19.99% after a 61-day notice period).
• After the reported transactions, 667, L.P. beneficially owns 212,188 warrants and Baker Brothers Life Sciences, L.P. beneficially owns 2,493,602 warrants.
• Julian C. Baker and Felix J. Baker may be deemed to have indirect pecuniary interests in the warrants due to their ownership interests in Baker Biotech Capital, L.P. and Baker Brothers Life Sciences Capital L.P., respectively.
• Baker Bros. Advisors LP serves as the investment advisor to the Funds and has complete discretion over investment and voting power.

Sentiment

Score: 7

Explanation: The document indicates a significant investment by a reputable firm, suggesting a positive outlook for Madrigal Pharmaceuticals. However, it's a regulatory filing, so the sentiment is moderately positive.

Positives

• Baker Bros.' investment signals confidence in Madrigal Pharmaceuticals.
• The warrants provide potential future capital for Madrigal Pharmaceuticals if exercised.

Risks

• The warrants are subject to an ownership limitation, which could restrict the extent to which they can be exercised.
• The value of the warrants is dependent on the future performance of Madrigal Pharmaceuticals' common stock.

Future Outlook

The document does not contain specific forward-looking statements regarding Madrigal Pharmaceuticals' future performance.

Industry Context

Baker Bros. Advisors is a well-known healthcare investment firm, so their investment in Madrigal Pharmaceuticals is noteworthy within the biotech industry.

Comparison to Industry Standards

• It is common for investment firms like Baker Bros. to acquire warrants in biotech companies as part of financing agreements.
• The specific terms of the warrants, such as the exercise price and ownership limitations, are typical for these types of transactions.
• Comparable companies that have received investments from Baker Bros. include companies such as Seagen and Incyte.

Stakeholder Impact

• Shareholders may view the investment positively, as it signals confidence in the company.
• The potential exercise of warrants could dilute existing shareholders' ownership.
• The capital raised from the warrant exercise could be used to fund research and development, benefiting the company and potentially patients.

Key Dates